Comparison of fully-automated radiosyntheses of [(11)C]erlotinib for preclinical and clinical use starting from in target produced [(11)C]CO(2) or [(11)C]CH(4)

BACKGROUND: [(11)C]erlotinib has been proposed as a PET tracer to visualize the mutational status of the epidermal growth factor receptor (EGFR) in cancer patients. For clinical use, a stable, reproducible and high-yielding radiosynthesis method is a prerequisite. In this work, two production scheme...

Descripción completa

Detalles Bibliográficos
Autores principales: Philippe, Cécile, Mairinger, Severin, Pichler, Verena, Stanek, Johann, Nics, Lukas, Mitterhauser, Markus, Hacker, Marcus, Wanek, Thomas, Langer, Oliver, Wadsak, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976684/
https://www.ncbi.nlm.nih.gov/pubmed/29888317
http://dx.doi.org/10.1186/s41181-018-0044-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976684/
https://www.ncbi.nlm.nih.gov/pubmed/29888317
http://dx.doi.org/10.1186/s41181-018-0044-1

Ejemplares similares